Unsanctifying the sanctuary: Challenges and opportunities with brain metastases

Shannon Puhalla, William Elmquist, David Freyer, Lawrence Kleinberg, Chris Adkins, Paul Lockman, John McGregor, Leslie Muldoon, Gary Nesbit, David Peereboom, Quentin Smith, Sara Walker, Edward Neuwelt

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

While the use of targeted therapies, particularly radiosurgery, has broadened therapeutic options for CNS metastases, patients respond minimally and prognosis remains poor. The inability of many systemic chemotherapeutic agents to penetrate the blood-brain barrier (BBB) has limited their use and allowed brain metastases to become a burgeoning clinical challenge. Adequate preclinical models that appropriately mimic the metastatic process, the BBB, and blood-tumor barriers (BTB) are needed to better evaluate therapies that have the ability to enhance delivery through or penetrate into these barriers and to understand the mechanisms of resistance to therapy. The heterogeneity among and within different solid tumors and subtypes of solid tumors further adds to the difficulties in determining the most appropriate treatment approaches and methods of laboratory and clinical studies. This review article discusses therapies focused on prevention and treatment of CNS metastases, particularly regarding the BBB, and the challenges and opportunities these therapies present.

Original languageEnglish (US)
Pages (from-to)639-651
Number of pages13
JournalNeuro-Oncology
Volume17
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Neoplasm Metastasis
Brain
Blood-Brain Barrier
Therapeutics
Neoplasms
Radiosurgery

Keywords

  • brain metastases
  • CNS sanctuary
  • imaging
  • prevention
  • therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Puhalla, S., Elmquist, W., Freyer, D., Kleinberg, L., Adkins, C., Lockman, P., ... Neuwelt, E. (2015). Unsanctifying the sanctuary: Challenges and opportunities with brain metastases. Neuro-Oncology, 17(5), 639-651. https://doi.org/10.1093/neuonc/nov023

Unsanctifying the sanctuary : Challenges and opportunities with brain metastases. / Puhalla, Shannon; Elmquist, William; Freyer, David; Kleinberg, Lawrence; Adkins, Chris; Lockman, Paul; McGregor, John; Muldoon, Leslie; Nesbit, Gary; Peereboom, David; Smith, Quentin; Walker, Sara; Neuwelt, Edward.

In: Neuro-Oncology, Vol. 17, No. 5, 01.05.2015, p. 639-651.

Research output: Contribution to journalArticle

Puhalla, S, Elmquist, W, Freyer, D, Kleinberg, L, Adkins, C, Lockman, P, McGregor, J, Muldoon, L, Nesbit, G, Peereboom, D, Smith, Q, Walker, S & Neuwelt, E 2015, 'Unsanctifying the sanctuary: Challenges and opportunities with brain metastases', Neuro-Oncology, vol. 17, no. 5, pp. 639-651. https://doi.org/10.1093/neuonc/nov023
Puhalla S, Elmquist W, Freyer D, Kleinberg L, Adkins C, Lockman P et al. Unsanctifying the sanctuary: Challenges and opportunities with brain metastases. Neuro-Oncology. 2015 May 1;17(5):639-651. https://doi.org/10.1093/neuonc/nov023
Puhalla, Shannon ; Elmquist, William ; Freyer, David ; Kleinberg, Lawrence ; Adkins, Chris ; Lockman, Paul ; McGregor, John ; Muldoon, Leslie ; Nesbit, Gary ; Peereboom, David ; Smith, Quentin ; Walker, Sara ; Neuwelt, Edward. / Unsanctifying the sanctuary : Challenges and opportunities with brain metastases. In: Neuro-Oncology. 2015 ; Vol. 17, No. 5. pp. 639-651.
@article{e4af83ef7e004aa383585f3b4dd2c8b7,
title = "Unsanctifying the sanctuary: Challenges and opportunities with brain metastases",
abstract = "While the use of targeted therapies, particularly radiosurgery, has broadened therapeutic options for CNS metastases, patients respond minimally and prognosis remains poor. The inability of many systemic chemotherapeutic agents to penetrate the blood-brain barrier (BBB) has limited their use and allowed brain metastases to become a burgeoning clinical challenge. Adequate preclinical models that appropriately mimic the metastatic process, the BBB, and blood-tumor barriers (BTB) are needed to better evaluate therapies that have the ability to enhance delivery through or penetrate into these barriers and to understand the mechanisms of resistance to therapy. The heterogeneity among and within different solid tumors and subtypes of solid tumors further adds to the difficulties in determining the most appropriate treatment approaches and methods of laboratory and clinical studies. This review article discusses therapies focused on prevention and treatment of CNS metastases, particularly regarding the BBB, and the challenges and opportunities these therapies present.",
keywords = "brain metastases, CNS sanctuary, imaging, prevention, therapy",
author = "Shannon Puhalla and William Elmquist and David Freyer and Lawrence Kleinberg and Chris Adkins and Paul Lockman and John McGregor and Leslie Muldoon and Gary Nesbit and David Peereboom and Quentin Smith and Sara Walker and Edward Neuwelt",
year = "2015",
month = "5",
day = "1",
doi = "10.1093/neuonc/nov023",
language = "English (US)",
volume = "17",
pages = "639--651",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Unsanctifying the sanctuary

T2 - Challenges and opportunities with brain metastases

AU - Puhalla, Shannon

AU - Elmquist, William

AU - Freyer, David

AU - Kleinberg, Lawrence

AU - Adkins, Chris

AU - Lockman, Paul

AU - McGregor, John

AU - Muldoon, Leslie

AU - Nesbit, Gary

AU - Peereboom, David

AU - Smith, Quentin

AU - Walker, Sara

AU - Neuwelt, Edward

PY - 2015/5/1

Y1 - 2015/5/1

N2 - While the use of targeted therapies, particularly radiosurgery, has broadened therapeutic options for CNS metastases, patients respond minimally and prognosis remains poor. The inability of many systemic chemotherapeutic agents to penetrate the blood-brain barrier (BBB) has limited their use and allowed brain metastases to become a burgeoning clinical challenge. Adequate preclinical models that appropriately mimic the metastatic process, the BBB, and blood-tumor barriers (BTB) are needed to better evaluate therapies that have the ability to enhance delivery through or penetrate into these barriers and to understand the mechanisms of resistance to therapy. The heterogeneity among and within different solid tumors and subtypes of solid tumors further adds to the difficulties in determining the most appropriate treatment approaches and methods of laboratory and clinical studies. This review article discusses therapies focused on prevention and treatment of CNS metastases, particularly regarding the BBB, and the challenges and opportunities these therapies present.

AB - While the use of targeted therapies, particularly radiosurgery, has broadened therapeutic options for CNS metastases, patients respond minimally and prognosis remains poor. The inability of many systemic chemotherapeutic agents to penetrate the blood-brain barrier (BBB) has limited their use and allowed brain metastases to become a burgeoning clinical challenge. Adequate preclinical models that appropriately mimic the metastatic process, the BBB, and blood-tumor barriers (BTB) are needed to better evaluate therapies that have the ability to enhance delivery through or penetrate into these barriers and to understand the mechanisms of resistance to therapy. The heterogeneity among and within different solid tumors and subtypes of solid tumors further adds to the difficulties in determining the most appropriate treatment approaches and methods of laboratory and clinical studies. This review article discusses therapies focused on prevention and treatment of CNS metastases, particularly regarding the BBB, and the challenges and opportunities these therapies present.

KW - brain metastases

KW - CNS sanctuary

KW - imaging

KW - prevention

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=84928898198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928898198&partnerID=8YFLogxK

U2 - 10.1093/neuonc/nov023

DO - 10.1093/neuonc/nov023

M3 - Article

C2 - 25846288

AN - SCOPUS:84928898198

VL - 17

SP - 639

EP - 651

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 5

ER -